The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Topical treatment of melasma
Open accessAbstract
Melasma is a common hypermelanotic disorder affecting the face that is associated with considerable psychological impacts. The management of melasma is challenging and requires a long-term treatment plan. In addition to avoidance of aggravating factors like oral pills and ultraviolet exposure, topical therapy has remained the mainstay of treatment. Multiple options for topical treatment are available, of which hydroquinone (HQ) is the most commonly prescribed agent. Besides HQ, other topical agents for which varying degrees of evidence for clinical efficacy exist include azelaic acid, kojic acid, retinoids, topical steroids, glycolic acid, mequinol, and arbutin. Topical medications modify various stages of melanogenesis, the most common mode of action being inhibition of the enzyme, tyrosinase. Combination therapy is the preferred mode of treatment for the synergism and reduction of untoward effects. The most popular combination consists of HQ, a topical steroid, and retinoic acid. Prolonged HQ usage may lead to untoward effects like depigmentation and exogenous ochronosis. The search for safer alternatives has given rise to the development of many newer agents, several of them from natural sources. Well-designed controlled clinical trials are needed to clarify their role in the routine management of melasma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Draelos, Z. D. (2007) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2007.00144.x · Cited by 390
Inhibitory effect of magnesium l-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo
Kameyama, K., Sakai, C., Kondoh, S., Yonemoto, K., Nishiyama, S., Tagawa, M., Murata, T., Ohnuma, T., Quigley, J., Dorsky, A., et al. (1996) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(96)90830-0 · Cited by 242 · cited 1×
“[50] Niacinamide Niacinamide (nicotinamide), the biologically active amide form of niacin (vitamin B 3 ), can reduce pigmentation by reversibly preventing the transfer of melanosomes from melanocytes to the keratinocytes.”
A double‐blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma
Espinal‐Perez, L. E., Moncada, B., & Castanedo‐Cazares, J. P. (2004) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2004.02134.x · Cited by 180
Topical liquiritin improves melasma
Amer, M., & Metwalli, M. (2000) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2000.00943.x · Cited by 145 · cited 1×
“[54] Flavonoids [12] Flavonoids are naturally occurring polyphenolic compounds that have well-known anti-in fl ammatory, antioxidant, antiviral, and anticarcinogenic properties.”
Protective effect of magnesium-l-ascorbyl-2 phosphate against skin damage induced by UVB irradiation
Kobayashi*, S., Takehana, M., Itoh, S., & Ogata, E. (1996) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1996.tb02447.x · Cited by 56 · cited 1×
“MAP has a protective effect against UVB radiation [49] and it inhibits melanogenesis in vitro and in vivo .”
Cited by
Kojic acid applications in cosmetic and pharmaceutical preparations
Saeedi, M., Eslamifar, M., & Khezri, K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.006 · Cited by 419
Metadata
- Authors
- Bandyopadhyay, D.
- Venue
- Indian Journal of Dermatology
- Publisher
- Medknow
- Published
- 2009
- Volume
- 54
- Issue
- 4
- Pages
- 303
- ISSN
- 0019-5154 (ISSN-L)
- OpenAlex
- W2146652970
- Cited by
- 169
- References
- 5
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical treatment of melasma. https://app.cochat.ai/papers/10.4103/0019-5154.57602
- The paper
- Bandyopadhyay, D. (2009). Topical treatment of melasma. Indian Journal of Dermatology. https://doi.org/10.4103/0019-5154.57602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.